Cargando…
Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849928/ https://www.ncbi.nlm.nih.gov/pubmed/33552547 http://dx.doi.org/10.2144/fsoa-2020-0146 |